Healthcare -
Biotechnology - NASDAQ - US
$ 5.8
2.11 %
$ 2.47 B
Market Cap
-3.15
P/E
1. INTRINSIC VALUE
Balance Sheet
Recursion Pharmaceuticals, Inc.
| Current Assets | 714 M |
| Cash & Short-Term Investments | 594 M |
| Receivables | 49.2 M |
| Other Current Assets | 70.8 M |
| Non-Current Assets | 734 M |
| Long-Term Investments | 0 |
| PP&E | 233 M |
| Other Non-Current Assets | 501 M |
| Current Liabilities | 187 M |
| Accounts Payable | 21.6 M |
| Short-Term Debt | 22.2 M |
| Other Current Liabilities | 144 M |
| Non-Current Liabilities | 226 M |
| Long-Term Debt | 19 M |
| Other Non-Current Liabilities | 207 M |
EFFICIENCY
Earnings Waterfall
Recursion Pharmaceuticals, Inc.
| Revenue | 58.8 M |
| Cost Of Revenue | 45.2 M |
| Gross Profit | 13.6 M |
| Operating Expenses | 493 M |
| Operating Income | -479 M |
| Other Expenses | -15.3 M |
| Net Income | -464 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Recursion Pharmaceuticals, Inc.
| Net Income | -464 M |
| Depreciation & Amortization | 36.5 M |
| Capital Expenditures | -13.7 M |
| Stock-Based Compensation | 81.7 M |
| Change in Working Capital | 0 |
| Others | -52.1 M |
| Free Cash Flow | -373 M |
Wall Street Analysts Price Targets
Recursion Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for RXRX of $8.75 , with forecasts ranging from
a
low of
$6 to a high of $12 .
RXRX Lowest Price Target
Wall Street Target
6 USD
3.45%
RXRX Average Price Target
Wall Street Target
8.75 USD
50.86%
RXRX Highest Price Target
Wall Street Target
12 USD
106.90%
4. DIVIDEND
ANALYSIS
RXRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Recursion Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.41 M USD 1
6-9 MONTHS
1.19 M USD 3
9-12 MONTHS
2.06 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
globenewswire.com
- 1 day ago
2 Beaten-Down Stocks With Incredible Upside Potential
Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,000% over the past three years, and Abivax, a France-based drugmaker, is up by more than 800% this year following strong clinical data.
fool.com
- 3 days ago
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
zacks.com
- 1 week ago
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
zacks.com
- 1 week ago
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST.
globenewswire.com
- 1 week ago
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Clinical-stage biotech Recursion Pharmaceuticals' (RXRX -2.85%) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving them with an almost 3% decline at market close.
fool.com
- 1 week ago
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Tempus AI and Recursion Pharmaceuticals are fine ways to play the AI revolution from the health angle.
247wallst.com
- 1 week ago
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
Are Americans saving enough money to fund a comfortable retirement? Probably not.
fool.com
- 1 week ago
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
Imagine you stepped into the dimly lit hospital meeting room to pitch a new cancer‑diagnostic deal. You flick through slides powered by Palantir Technologies Inc.'s PLTR Foundry platform, showcasing data transparency and precision that would make legacy pharma pipelines look prehistoric.
benzinga.com
- 1 week ago
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
zacks.com
- 1 week ago
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
zacks.com
- 2 weeks ago
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
zacks.com
- 2 weeks ago
8. Profile
Summary
Recursion Pharmaceuticals, Inc. RXRX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.47 B
Dividend Yield
0.00%
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Contact
41 South Rio Grande Street, Salt Lake City, UT, 84101
https://www.recursion.com
IPO
Date
April 16, 2021
Employees
800
Officers
Mr. Ben R. Taylor
Chief Financial Officer & President of Recursion UK
Kevin Leggat
Vice President of Finance & Accounting
Dr. David J. Mauro M.D., Ph.D.
Chief Medical Officer
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. Najat Khan Ph.D.
Chief R&D Officer, Chief Commercial Officer and Director
Dr. David Hallett Ph.D.
Chief Scientific Officer
Mr. Nathan Hatfield J.D., M.B.A.
Chief Legal Officer & General Counsel
Ms. Erica Fox
Chief People and Impact Officer
Ms. Kristen Rushton M.B.A.
Chief Operating Officer